Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories, Inc. Recalls

All product recalls associated with Dr. Reddy's Laboratories, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

167

Past Year

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 81–100 of 167 recalls

Ranitidine Capsules 300mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Capsules 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class II

1...3 456 7...9

Page 5 of 9Next

Moderate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 75mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (GeriCare) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 75mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ranitidine Tablets 150mg (Dr. Reddy's) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAOct 1, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Divalproex Sodium Tablets (Dr. Reddy's) – Humidity Exposure (2019)

cGMP deviations: Product was exposed above 50% relative humidity levels during packaging operations.

Class IIModerate

FDAApr 11, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Docetaxel Injection (Dr. Reddy's) – Container Defect (2019)

Defective Container: complaint for seal and cap vial issues that could lead to a lack of sterility assurance.

Class IIModerate

FDAMar 6, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Esomeprazole Capsules (Dr. Reddy's) – Color Deviation (2019)

Discoloration: Esomeprazole Magnesium DR Capsules (40mg) may contain brown pellets.

Class IIILow

FDAFeb 6, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Divalproex Sodium Tablets (Dr. Reddy's) – Dissolution Failure (2019)

Failed Dissolution Specifications: Out of specification results observed for high dissolution.

Class IIModerate

FDAJan 31, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Ezetimibe Simvastatin Tablets (Dr. Reddy's) – foreign substance (2019)

Presence of Foreign Substance: Product complaint of black speckles observed on tablets.

Class IIModerate

FDAJan 15, 2019Nationwide• Dr. Reddy's Laboratories, Inc.

Clopidogrel Tablets (Dr. Reddy's) – failed dissolution (2018)

Failed dissolution specification -Two additional lots being recalled due to Out-of-Specification results observed for dissolution at 18th month stability testing.

Class IIModerate

FDADec 10, 2018Nationwide• Dr. Reddy's Laboratories, Inc.

Clopidogrel Tablets (Dr. Reddy's) – Dissolution Failure (2018)

Failed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.

Class IIModerate

FDANov 7, 2018Nationwide• Dr. Reddy's Laboratories, Inc.

Levetiracetam Injection (Dr. Reddy's) – Labeling Strength Error (2018)

Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).

Class IHigh

FDAOct 26, 2018Nationwide• Dr. Reddy's Laboratories, Inc.